Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Coverage Of Amyloid PET Scans In Alzheimer’s Expected To Be ‘Consistent,’ Even Without National Standard, CMS Says

Executive Summary

Medicare has finally rescinded its 10-year-old national restrictions on covering the diagnostic now that advances in amyloid plaque-removing drugs have underscored the importance of PET scans.

You may also be interested in...



CTAD 2023: Subcutaneous Leqembi Bests I.V., Could Open Access

The first results for subcutaneous lecanemab in early Alzheimer’s disease show better amyloid clearance with slightly higher ARIA rates than the I.V. version. Eisai also presented Phase III Clarity AD updates and initial long-term extension data.

New Alzheimer’s Drug Access Should Ease Somewhat Under Updated Medicare PET Scan Proposal

After a decade of curtailed use, new drugs make wider availability important for patient selection and safety, CMS says in a new amyloid PET scan proposal. 

Lilly’s Dosing Scheme For Donanemab In Alzheimer’s And Treatment Cost Effectiveness

Firm’s aggressive approach to amyloid plaque removal means a shorter duration of treatment and potentially lower costs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel